Distribution of factors by type of CBF AML at diagnosis
| Factors at diagnosis . | t(8;21); n = 38 . | inv(16); n = 55 . | P . |
|---|---|---|---|
| Sex | |||
| Male, no. (%) | 28/38 (74) | 31/55 (56) | — |
| Female, no. (%) | 10/38 (26) | 24/55 (44) | ns |
| Age | |||
| No. of patients | 36 | 53 | — |
| Median, y (range) | 50 (19-73) | 42 (19-72) | .030 |
| FAB subtype | |||
| M2 (%) | 23/34 (68) | 2/51 (4) | < .001 |
| M4 (%) | 2/34 (6) | 46/51 (90) | — |
| Other (%) | 9/34 (26) | 3/51 (6) | — |
| WBC | |||
| No. of patients | 36 | 51 | — |
| Median, × 109/L (range) | 13 (2-152) | 36 (2-157) | .013 |
| BM blast | |||
| No. of patients | 31 | 43 | — |
| Median, % (range) | 52 (6-90) | 74 (10-100) | .014 |
| Overall survival | |||
| No. of patients | 36 | 53 | — |
| Median, d | 1430 | 1661 | ns |
| Additional cytogenetic aberrations | |||
| None (%) | 11/36 (31) | 36/53 (68) | .001 |
| Trisomy 8 (%) | 3/36 (8) | 8/53 (15) | ns |
| del(9q)/-9 (%) | 3/36 (8) | 0/53 (0) | ns |
| Trisomy 22 (%) | 0/36 (0) | 6/53 (11) | .0761 |
| -Y/males (%) | 15/27 (56) | 1/29 (3) | < .001 |
| -X/females (%) | 5/9 (56) | 0/24 (0) | < .001 |
| Other (%) | 4/36 (11) | 11/53 (21) | ns |
| Molecular genetic aberrations | |||
| FLT3-ITD (%) | 3/34 (9) | 1/46 (2) | ns |
| FLT3-TKD (%) | 2/31 (6) | 7/45 (15) | ns |
| KIT mutation (%) | 5/31 (16) | 8/34 (24) | ns |
| Exon 8 (%) | 2/31 (6) | 4/34 (12) | ns |
| Exon 17 (%) | 3/31 (10) | 4/34 (12) | ns |
| NRAS mutation (%) | 4/26 (15) | 14/34 (41) | .057 |
| Exon 1 (%) | 2/26 (8) | 6/34 (18) | ns |
| Exon 2 (%) | 2/26 (8) | 8/34 (24) | ns |
| Factors at diagnosis . | t(8;21); n = 38 . | inv(16); n = 55 . | P . |
|---|---|---|---|
| Sex | |||
| Male, no. (%) | 28/38 (74) | 31/55 (56) | — |
| Female, no. (%) | 10/38 (26) | 24/55 (44) | ns |
| Age | |||
| No. of patients | 36 | 53 | — |
| Median, y (range) | 50 (19-73) | 42 (19-72) | .030 |
| FAB subtype | |||
| M2 (%) | 23/34 (68) | 2/51 (4) | < .001 |
| M4 (%) | 2/34 (6) | 46/51 (90) | — |
| Other (%) | 9/34 (26) | 3/51 (6) | — |
| WBC | |||
| No. of patients | 36 | 51 | — |
| Median, × 109/L (range) | 13 (2-152) | 36 (2-157) | .013 |
| BM blast | |||
| No. of patients | 31 | 43 | — |
| Median, % (range) | 52 (6-90) | 74 (10-100) | .014 |
| Overall survival | |||
| No. of patients | 36 | 53 | — |
| Median, d | 1430 | 1661 | ns |
| Additional cytogenetic aberrations | |||
| None (%) | 11/36 (31) | 36/53 (68) | .001 |
| Trisomy 8 (%) | 3/36 (8) | 8/53 (15) | ns |
| del(9q)/-9 (%) | 3/36 (8) | 0/53 (0) | ns |
| Trisomy 22 (%) | 0/36 (0) | 6/53 (11) | .0761 |
| -Y/males (%) | 15/27 (56) | 1/29 (3) | < .001 |
| -X/females (%) | 5/9 (56) | 0/24 (0) | < .001 |
| Other (%) | 4/36 (11) | 11/53 (21) | ns |
| Molecular genetic aberrations | |||
| FLT3-ITD (%) | 3/34 (9) | 1/46 (2) | ns |
| FLT3-TKD (%) | 2/31 (6) | 7/45 (15) | ns |
| KIT mutation (%) | 5/31 (16) | 8/34 (24) | ns |
| Exon 8 (%) | 2/31 (6) | 4/34 (12) | ns |
| Exon 17 (%) | 3/31 (10) | 4/34 (12) | ns |
| NRAS mutation (%) | 4/26 (15) | 14/34 (41) | .057 |
| Exon 1 (%) | 2/26 (8) | 6/34 (18) | ns |
| Exon 2 (%) | 2/26 (8) | 8/34 (24) | ns |
ns indicates nonsignificant; —, not applicable.